(Q34508065)

English

Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

colorectal cancer

1 reference

based on heuristic

inferred from title

quality of life

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Marc Peeters

4

0 references

author name string

Dawn Odom

1

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Beth Barber

2

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Lee Bennett

3

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Zhongyun Zhao

5

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

James Kaye

6

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Michael Wolf

7

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Jeffrey Wiezorek

8

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

publication date

29 December 2010

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

International Journal of Colorectal Disease

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

26

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

173-181

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Psychometric evaluation of the FACT Colorectal Cancer Symptom Index (FCSI-9): reliability, validity, responsiveness, and clinical meaningfulness

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024508

7 July 2018

Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024508

7 July 2018

First-line therapeutic strategies in metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024508

7 July 2018

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024508

7 July 2018

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024508

7 July 2018

Cancer statistics, 2008

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024508

7 July 2018

Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024508

7 July 2018

Cetuximab for the treatment of colorectal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024508

7 July 2018

Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024508

7 July 2018

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024508

7 July 2018

Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024508

7 July 2018

Global cancer statistics, 2002

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024508

7 July 2018

US valuation of the EQ-5D health states: development and testing of the D1 valuation model.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024508

7 July 2018

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024508

7 July 2018

What Are the Most Important Symptom Targets When Treating Advanced Cancer? A Survey of Providers in the National Comprehensive Cancer Network (NCCN)

1 reference

https://api.crossref.org/works/10.1007%2FS00384-010-1112-5

21 January 2018

Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy.

1 reference

https://api.crossref.org/works/10.1007%2FS00384-010-1112-5

21 January 2018

Psychological effects of cetuximab-induced cutaneous rash in advanced colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS00384-010-1112-5

21 January 2018

Learning to live with missing quality-of-life data in advanced-stage disease trials.

1 reference

https://api.crossref.org/works/10.1007%2FS00384-010-1112-5

21 January 2018

Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3024508

27 October 2018

Health-related quality of life as a valid outcome in the treatment of advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00384-010-1112-5

21 January 2018

Identifiers

10.1007/S00384-010-1112-5

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34508065&oldid=2196723926"